Graham D L, Knott T J, Jones T C, Pease R J, Pullinger C R, Scott J
Division of Molecular Medicine, MRC Clinical Research Centre, Harrow, Middlesex, U.K.
Biochemistry. 1991 Jun 4;30(22):5616-21. doi: 10.1021/bi00236a040.
Apolipoprotein B has an obligatory role in the production of chylomicrons, VLDL, and LDL. Familial hypobetalipoproteinemia is a codominant disorder characterized by reduced levels of apo B containing lipoproteins in plasma. We have previously described mutations of the apo B gene in persons with hypobetalipoproteinemia that predict truncated forms of apo B designated apo B29 (1305 amino acid residues) and apo B39 (1799 residues). Apo B39 was present in the VLDL and LDL fractions of plasma, but apo B29 was not detected in the lipoprotein or infranatant fractions of plasma. Here we have investigated the regions of apo B necessary for apo B containing lipoprotein secretion by expression of constructs designed to express truncated forms of apo B. Apo B13 (583 residues), apo B17 (784 residues), apo B23 (1084 residues), apo B29 (1306 residues), and apo B41 (1880 residues) were transiently expressed in HepG2 cells, and apo B23 and apo B41 were stably expressed in McArdle 7777 cells. Lipoprotein (d less than 1.25 g/mL) and infranatant (d greater than 1.25 g/mL) fractions of conditioned medium were analyzed by immunoprecipitation and SDS-PAGE. The distribution between lipoprotein and infranatant fractions varied: apo B41 was found solely in the lipoprotein fraction; apo B29, apo B23, and apo B17 were present in both fractions, but with stepwise truncation, progressively more apo B was recovered in the infranatant; apo B13 was only in the infranatant. These results demonstrate that deletion from the carboxyl terminal of apo B41 results in a gradual loss of the ability of the truncated proteins to form buoyant lipoprotein particles.
载脂蛋白B在乳糜微粒、极低密度脂蛋白(VLDL)和低密度脂蛋白(LDL)的产生中起关键作用。家族性低β脂蛋白血症是一种共显性疾病,其特征是血浆中含载脂蛋白B的脂蛋白水平降低。我们之前描述过低β脂蛋白血症患者中载脂蛋白B基因的突变,这些突变预测会产生截短形式的载脂蛋白B,分别命名为载脂蛋白B29(1305个氨基酸残基)和载脂蛋白B39(1799个残基)。载脂蛋白B39存在于血浆的VLDL和LDL组分中,但在血浆的脂蛋白或上清组分中未检测到载脂蛋白B29。在此,我们通过表达旨在表达截短形式载脂蛋白B的构建体,研究了载脂蛋白B含脂蛋白分泌所需的区域。载脂蛋白B13(583个残基)、载脂蛋白B17(784个残基)、载脂蛋白B23(1084个残基)、载脂蛋白B29(1306个残基)和载脂蛋白B41(1880个残基)在HepG2细胞中瞬时表达,载脂蛋白B23和载脂蛋白B41在McArdle 7777细胞中稳定表达。通过免疫沉淀和SDS-PAGE分析条件培养基的脂蛋白(d小于1.25 g/mL)和上清(d大于1.25 g/mL)组分。脂蛋白和上清组分之间的分布各不相同:载脂蛋白B41仅存在于脂蛋白组分中;载脂蛋白B29、载脂蛋白B23和载脂蛋白B17存在于两个组分中,但随着逐步截短,上清中回收的载脂蛋白B逐渐增多;载脂蛋白B13仅存在于上清中。这些结果表明,从载脂蛋白B41的羧基末端缺失会导致截短蛋白形成漂浮脂蛋白颗粒的能力逐渐丧失。